文献速递类风湿关节炎

人脐带间充质干细胞移植联合IFN-γ治疗协同改善类风湿关节炎患者临床结局

Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2020-06-19

该研究先在胶原诱导性关节炎小鼠模型中评估野生型或IFN-γR-/-间充质干细胞移植(MSCT),随后在63例对常规治疗反应不佳的类风湿关节炎(RA)患者中开展1/2期随机对照研究,比较MSCT单药(n=32)与MSCT联合重组人IFN-γ(n=31)治疗并随访1年。3个月随访显示,联合组疗效和ACR20反应率均达93.3%,单药组为53.3%(p<0.05);1年随访两组均未出现新的或非预期安全性问题。结论提示IFN-γ是决定MSCT治疗RA疗效的关键因素,MSC联合IFN-γ策略可大幅提高MSC治疗RA的临床疗效。

要点

  • 小鼠模型中野生型MSCT改善CIA临床严重度,而IFN-γR-/- MSCT加重滑膜炎及关节软骨损伤。
  • 63例RA患者随机分为MSCT单药组(n=32)与MSCT联合重组人IFN-γ组(n=31),随访1年。
  • 3个月时联合组疗效和ACR20反应率达93.3%,单药组为53.3%(p<0.05)。

核心结论

  • IFN-γ是决定MSCT治疗RA疗效的关键因素,MSC联合IFN-γ策略可大幅提高MSC治疗RA的临床疗效。

研究设计与样本

  • 先在胶原诱导性关节炎(CIA)小鼠模型中评估野生型或IFN-γR-/- MSCT,随后开展1/2期随机对照研究。
  • 纳入63例对常规临床治疗反应不佳的RA患者,随机分为MSCT单药组(n=32)或MSCT联合重组人IFN-γ组(n=31),随访1年。
  • 主要终点为EULAR良好或中度反应率评估的疗效,以及3个月时达到ACR20反应率的患者比例。

主要发现

  • 小鼠研究中野生型MSCT显著改善CIA临床严重度,而IFN-γR-/- MSCT加重滑膜炎及关节和软骨损伤。
  • 3个月随访时MSCT单药组53.3%患者获得疗效和ACR20反应,MSCT联合IFN-γ组为93.3%(p<0.05)。
  • 1年随访中两组均未出现新的或非预期安全性问题。

关键数值与推荐

  • 3个月随访时MSCT单药组疗效和ACR20反应率为53.3%,MSCT联合IFN-γ组为93.3%(p<0.05)。

临床怎么用

  • 对常规治疗反应不佳的RA患者,可考虑MSC联合IFN-γ策略以提高MSC治疗疗效。
  • 治疗决策需结合1年随访安全性数据,联合方案未出现新的或非预期安全问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To clarify the key role of circulating interferon-γ (IFN-γ) and to improve the clinical efficacy of mesenchymal stem cell (MSC) transplantation (MSCT) in patients with rheumatoid arthritis (RA). METHODS: Study of wild-type or IFN-γR-/- MSCT was first evaluated in a murine model of collagen-induced arthritis (CIA) following which a phase 1/2 randomised controlled study was conducted in 63 patients with RA who responded poorly to regular clinical treatments. Subjects were randomly assigned to an MSCT monotherapy group (n=32) or an MSCT plus recombinant human IFN-γ treatment group (n=31), with 1 year of follow-up. The primary end points consisted of efficacy as assessed as good or moderate EULAR response rates and the proportion of patients at 3 months attaining American College of Rheumatology 20 (ACR20) response rates. RESULTS: In the murine studies, wild-type MSCT significantly improved the clinical severity of CIA, while IFN-γR-/- MSCT aggravated synovitis, and joint and cartilage damage. Transitioning from the murine to the clinical study, the 3-month follow-up results showed that the efficacy and ACR20 response rates were attained in 53.3% patients with MSCT monotherapy and in 93.3% patients with MSCT combined with IFN-γ treatment (p<0.05). No new or unexpected safety issues were encountered in 1-year follow-up for either treatment group. CONCLUSIONS: The results of this study show that IFN-γ is a key factor in determining the efficacy of MSCT in the treatment of RA, and that an MSC plus IFN-γ combination therapeutic strategy can greatly improve the clinical efficacy of MSC-based therapy in RA patients.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. He X, Yang Y, Yao M, et al. Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis. Ann Rheum Dis. 2020. PMID: 32561603. doi:10.1136/annrheumdis-2020-217798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。